AXSM Axsome Therapeutics, Inc.
FY2025 10-K
Axsome Therapeutics, Inc. (AXSM) filed its fiscal year 2025 10-K annual report with the SEC on Feb 23, 2026. This page provides AI-powered analysis of the filing, including business overview, management discussion, risk factors, and key financial metrics from XBRL data.
AI Filing AnalysisFY2025 10-K
Business Overview
- • Core business: Development, commercialization, and sales of pharmaceutical products for CNS disorders, including AUVELITY, SUNOSI, and launch of SYMBRAVO in 2025
- • New product: Commercial launch of SYMBRAVO began June 2025, generating $6.6 million in net sales for the year, no sales in prior year
Risk Factors
- • Regulatory risk: FDA Breakthrough Therapy designation for AXS-05 for AD agitation may not expedite approval or guarantee marketing authorization
- • Geopolitical risk: EU sanctions on Russia extended to July 31, 2026, with potential supply chain and capital market disruptions impacting operations
Financial SummaryXBRL
Revenue
$638M
Net Income
-$183M
Operating Margin
-26.1%
Net Margin
-28.7%
ROE
-207.5%
Total Assets
$690M
EPS (Diluted)
$-3.68
Operating Cash Flow
-$93M
Source: XBRL data from Axsome Therapeutics, Inc. FY2025 10-K filing on SEC EDGAR. All figures in USD.
Get deeper insights on Axsome Therapeutics, Inc.
Access full AI analysis, insider trading data, fund holdings, and cross-signal detection on SignalX.